PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies
US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.
US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.